Drug Combination of DNA Topoisomerase I (TOP1) Inhibitors and Extracellular ATP Produces a Significant Increase in Beneficial An
Posted Oct 20 2010 8:00pm
Description of Invention: DNA topoisomerase inhibitors are a category of drugs used for cancer therapy. DNA topoisomerase 1 (TOP1) inhibitors, such as Camptothecin (CPT) and its structurally related analogues, bind to the TOP1 complex and prevent the religation of the single strand DNA molecules, ultimately leading to cell death. CPT and close analogues show anticancer activity in clinical trials treating ovarian, small-cell lung, and colorectal cancers, but also adverse drug reaction. By reducing the cytotoxic dose in the thousands of folds, the NIH scientists are able to target the tumor and reduce the cytotoxicity to normal cells. The instant invention discloses that the drug combination of DNA topoisomerase 1 (TOP1) inhibitors, such as the anti-cancer drug Camptothecin (CPT), and extracellular ATP produces a significant increase in beneficial anti-carcinoma cytotoxicity.
Applications: This invention may provide a new combination of drug with extracellular ATP to target various cancers for treatment.
Development Status: Pre-clinical stage of development
Inventors: Joseph Riss (NCI) Glenn Y Merlino (NCI) J. Carl Barrett (Novartis Institutes for BioMedical Research, Inc.)
For Licensing Information Please Contact: Betty Tong Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-594-6565 Fax: 301-402-0220